Cellceutix, a Beverly, MA-based developer of drugs for cancer and other diseases, says that the company and its former CEO George Evans have settled a compensation dispute. The company has agreed to buy 4.6 million shares of stock held by Evans, a former Pfizer lawyer, and/or his sons over the past three years for $1 million. In November, the Cellceutix told regulators that Evans sought $1.7 million in back salary and future compensation over a dispute about his pay at the firm.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
